F. Stephen Hodi

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

F. Stephen Hodi
Jan 7, 2025, 18:04 | Insight
Stephen Liu: What is the best way to assess response of brain metastases to systemic treatment?
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:…
Jan 2, 2025, 15:54 | Blog
Yakup Ergün: Final Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X: "Final, 10-Year…
Dec 24, 2024, 17:32 | Blog
Three-Year Overall Survival with Nivolumab + Relatlimab rela-nivo in Advanced Melanoma
Marco Donia shared on LinkedIn: "Three-Year Overall Survival with Nivolumab + Relatlimab (rela-nivo) in Advanced…
Dec 17, 2024, 06:25 | Opinion
Andrea Boutros: RELATIVITY-047 trial showing sustained benefit of Nivolumab plus Ipilimumab in advanced melanoma
Andrea Boutros, Medical Doctor and Oncology Resident at San Martino Polyclinic Hospital, shared on X:…
Nov 29, 2024, 15:37 | Insight
Giuseppe Tarantino: Genomic Heterogeneity and Ploidy predict resistance to Anti-PD-1 Therapy in Metastatic Melanoma
Giuseppe Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn: "Excited to share our…
Sep 24, 2024, 12:30 | Societies
11 ESMO24 presentations published on NEJM
At the 2024 ESMO Congress, 11 articles were presented that were published in NEJM, highlighting…
Aug 29, 2024, 11:25 | Insight
Article of the day, August 29th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 19, 2024, 11:57 | Insight
Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma
Katsuaki Maehara shared a post on X: "Melanoma Journal of Clinical Oncology. NCCN Guidelines recommended both…
All: 8 Posts: 1 - 100
Special Coverage